Tesla Faces 19% Drop in UK Registrations as Competition Intensifies 
Proxy Advisors Urge Vote Against ANZ’s Executive Pay Report Amid Scandal Fallout 
Michael Dell Pledges $6.25 Billion to Boost Children’s Investment Accounts Under Trump Initiative 
IKEA Launches First New Zealand Store, Marking Expansion Into Its 64th Global Market 
Hikvision Challenges FCC Rule Tightening Restrictions on Chinese Telecom Equipment 
GM Issues Recall for 2026 Chevrolet Silverado Trucks Over Missing Owner Manuals 
Trump Administration to Secure Equity Stake in Pat Gelsinger’s XLight Startup 
Airbus Faces Pressure After November Deliveries Dip Amid Industrial Setback 
UPS MD-11 Crash Prompts Families to Prepare Wrongful Death Lawsuit 
Microchip Technology Boosts Q3 Outlook on Strong Bookings Momentum 
Tesla Expands Affordable Model 3 Lineup in Europe to Boost EV Demand 
Wikipedia Pushes for AI Licensing Deals as Jimmy Wales Calls for Fair Compensation 
USPS Expands Electric Vehicle Fleet as Nationwide Transition Accelerates 
IKEA Expands U.S. Manufacturing Amid Rising Tariffs and Supply Chain Strategy Shift 
Netflix Nearing Major Deal to Acquire Warner Bros Discovery Assets 
YouTube Agrees to Follow Australia’s New Under-16 Social Media Ban 
ExxonMobil to Shut Older Singapore Steam Cracker Amid Global Petrochemical Downturn 
Merck Group announced on Wednesday, March 24, that it has assigned a new chief financial officer. The company picked Caroline Litchfield to be Robert Davis’s replacement and she will assume her post starting April 1.
Litchfield’s new appointment at the company
As per Reuters, Litchfield has been working for Merck since 1990. At that time, she joined the company as part of its unit in the U.K. Prior to her new assignment as CFO this year, she was in charge of Merck’s treasury, tax and investor relations.
She has also worked in the financial operations section for Merck’s Human Health. This unit is the pharmaceutical firm’s largest business to date.
In any case, she will be succeeding Rob Davis, who will leave his post as CFO. He will be taking over as the company’s new chief executive officer as the current CEO, Ken Frazier, already announced last month that he is retiring in June.
Litchfield’s expected contribution as the new CFO
The new assignments of chief officers also come as Merck is aiming for transformation. It wanted to diversify its offerings and go beyond the immuno-oncology business development. It was mentioned that Litchfield would be a big help in this transition as she takes on part of the responsibilities for this plan.
“Caroline’s appointment as our next CFO is the result of a combination of factors and most importantly, Caroline’s financial expertise, remarkable track record, and leadership as well as our commitment to developing talent and our succession planning for leadership roles,” Kenneth C. Frazier said in a press release.
Davis added, “Caroline’s passion for Merck’s mission and for the patients we serve guides every decision that she makes." He said he is also looking forward to working with Caroline and "to benefit from her expertise and leadership as we chart the course for Merck in the months and years ahead.”
In response to the warm welcome from her colleagues, Caroline Litchfield said that she is very honored to serve Merck as the new CFO. She went on to say that her assignment is even more meaningful as it comes at such a pivotal time when the company is transitioning to improve lives.
